ADVERTISEMENT

Biocon

Biocon settles with Janssen to commercialise biosimilar products in Europe, Canada, Japan

The US health regulator has accepted the company's Biologics License Application (BLA) for Bmab 1200 for review.

29 August 2024, 06:10 IST

Biocon settles with Janssen to commercialise biosimilar products in Europe, Canada, Japan

Biocon settles with Janssen to commercialise biosimilar products in Europe, Canada, Japan

Biocon settles with Janssen to commercialise biosimilar products in Europe, Canada, Japan

29 August 2024, 06:10 IST

Biocon boards defaced in Bengaluru

Unidentified persons sprayed black paint on at least two Biocon nameboards, an act captured in a viral video on the microblogging site 'X'.

22 July 2024, 21:28 IST

Biocon boards defaced in Bengaluru

Biocon boards defaced in Bengaluru

Biocon boards defaced in Bengaluru

22 July 2024, 21:28 IST

Biocon Biologics gets EMA nod to produce biosimilar Bevacizumab at Bengaluru plant

The Bengaluru facility has previously been approved to manufacture biosimilar Trastuzumab in September 2022.

24 June 2024, 06:39 IST

Biocon Biologics gets EMA nod to produce biosimilar Bevacizumab at Bengaluru plant

Biocon Biologics gets EMA nod to produce biosimilar Bevacizumab at Bengaluru plant

Biocon Biologics gets EMA nod to produce biosimilar Bevacizumab at Bengaluru plant

24 June 2024, 06:39 IST

Biocon Biologics secures USFDA approval for biosimilar product to treat ophthalmology conditions

The US Food and Drug Administration (USFDA) has approved Biocon's first-to-file application for Yesafili, a vascular endothelial growth factor inhibitor used to treat several different types of ophthalmology conditions.

21 May 2024, 07:17 IST

Biocon Biologics secures USFDA approval for biosimilar product to treat ophthalmology conditions

Biocon Biologics secures USFDA approval for biosimilar product to treat ophthalmology conditions

Biocon Biologics secures USFDA approval for biosimilar product to treat ophthalmology conditions

21 May 2024, 07:17 IST

Biocon to sell branded formulations business to Eris Lifesciences for Rs 1,242 crore

The deal, which is expected to close by April 15, 2024, includes the acquisition of insulin brands Basalog and Insugen which Eris said will help its diabetes treatment franchise reach 10 billion rupees in revenue, without specifying a timeline.

14 March 2024, 11:30 IST

Biocon to sell branded formulations business to Eris Lifesciences for Rs 1,242 crore

Biocon to sell branded formulations business to Eris Lifesciences for Rs 1,242 crore

Biocon to sell branded formulations business to Eris Lifesciences for Rs 1,242 crore

14 March 2024, 11:30 IST

Biocon gets over Rs 3 crore penalty over GST related issues

The company has received an order of adjudication imposing a penalty of Rs 3,03,78,465 dated February 22, 2024, from the office of Deputy Commissioner of Commercial Taxes, Divisional GST Office, Bengaluru.

23 February 2024, 11:39 IST

Biocon gets over Rs 3 crore penalty over GST related issues

Biocon gets over Rs 3 crore penalty over GST related issues

Biocon gets over Rs 3 crore penalty over GST related issues

23 February 2024, 11:39 IST

Biocon net profit more than doubles to Rs 126 cr in Q2FY24

The Bengaluru-headquartered company’s revenue grew 52% year-on-year to Rs 3,620 crore, led largely by a revenue rise of 97% in its biosimilars business segment.

11 November 2023, 00:41 IST

Biocon net profit more than doubles to Rs 126 cr in Q2FY24

Biocon net profit more than doubles to Rs 126 cr in Q2FY24

Biocon net profit more than doubles to Rs 126 cr in Q2FY24

11 November 2023, 00:41 IST

Official action indicated for Biocon arm's unit in Malaysia after USFDA inspection

The OAI (official action indicated) status may cause delay and/or withholding of pending product approvals or supplements from the facility, Biocon Ltd said in a regulatory filing.

18 October 2023, 10:45 IST

Official action indicated for Biocon arm's unit in Malaysia after USFDA inspection

Official action indicated for Biocon arm's unit in Malaysia after USFDA inspection

Official action indicated for Biocon arm's unit in Malaysia after USFDA inspection

18 October 2023, 10:45 IST

SII to double investment in Biocon's unit to $300 mn

Serum Institute of Life Sciences had already invested $150 million in Biocon Biologics in November 2022

26 April 2023, 01:10 IST

Serum subsidiary doubles investment in Biocon unit to $300 million

Serum subsidiary doubles investment in Biocon unit to $300 million

SII to double investment in Biocon's unit to $300 mn

26 April 2023, 01:10 IST

Biocon Biologics elevates Shreehas Tambe as MD and CEO

Tambe started out as a management trainee in 1997

06 December 2022, 00:53 IST

Biocon Biologics elevates Shreehas Tambe as MD and CEO

Biocon Biologics elevates Shreehas Tambe as MD and CEO

Biocon Biologics elevates Shreehas Tambe as MD and CEO

06 December 2022, 00:53 IST